Talee Bio is developing two inhaled gene therapy product candidates for cystic fibrosis: TL-101 (aerosolized recombinant AAV) and TL-102 (aerosolized lentiviral). Both candidates are described as mutation-agnostic and intended to treat pulmonary disease in all people with CF, including those without viable treatment options. TL-101 is being developed for single or multiple aerosolized doses; TL-102 is positioned as a potential one-dose cure for pulmonary manifestations. Both programs are in preclinical development with a stated goal of initiating clinical trials in 2020. The company is development-stage and has been founded by academic researchers from the University of Iowa and the Children’s Hospital of Philadelphia, with Militia Hill Ventures involved in the founding and support from Emily’s Entourage. The announcement was issued from Philadelphia and emphasizes expedited development through external funding.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2019